ADMA Biologics Sees Unusually High Options Volume (NASDAQ:ADMA)

ADMA Biologics Inc (NASDAQ:ADMA) was the target of unusually large options trading on Thursday. Stock traders bought 22,398 call options on the stock. This represents an increase of approximately 848% compared to the typical daily volume of 2,362 call options.

ADMA Biologics Stock Performance

NASDAQ ADMA opened at $9.25 on Friday. The company has a debt-to-equity ratio of 0.16, a current ratio of 6.71 and a quick ratio of 3.74. The stock’s 50 day simple moving average is $15.60 and its 200-day simple moving average is $16.42. The company has a market cap of $2.20 billion, a PE ratio of 15.42 and a beta of 0.51. ADMA Biologics has a 1-year low of $7.21 and a 1-year high of $25.67.

ADMA Biologics (NASDAQ:ADMA) last posted its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported $0.20 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.20. The firm had revenue of $139.16 million for the quarter, compared to analyst estimates of $139.80 million. ADMA Biologics had a net margin of 28.80% and a return on equity of 37.52%. ADMA Biologics’s quarterly revenue was up 18.4% on a year-over-year basis. During the same period in the previous year, the business posted $0.46 earnings per share. As a group, equities research analysts anticipate that ADMA Biologics will post 0.51 EPS for the current fiscal year.

Insider Buying and Selling

In other ADMA Biologics news, Director Steve Elms acquired 7,000 shares of the company’s stock in a transaction on Thursday, March 5th. The shares were bought at an average cost of $15.67 per share, with a total value of $109,690.00. Following the completion of the acquisition, the director owned 2,038,730 shares in the company, valued at approximately $31,946,899.10. This trade represents a 0.34% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, COO Kaitlin M. Kestenberg-Messina sold 10,096 shares of the business’s stock in a transaction that occurred on Monday, March 9th. The shares were sold at an average price of $15.63, for a total value of $157,800.48. Following the completion of the sale, the chief operating officer owned 466,600 shares of the company’s stock, valued at $7,292,958. This trade represents a 2.12% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 3.50% of the stock is owned by company insiders.

Institutional Trading of ADMA Biologics

Large investors have recently added to or reduced their stakes in the stock. Royal Bank of Canada boosted its position in shares of ADMA Biologics by 112.7% during the 1st quarter. Royal Bank of Canada now owns 95,885 shares of the biotechnology company’s stock valued at $1,903,000 after acquiring an additional 50,801 shares during the last quarter. Ashton Thomas Private Wealth LLC acquired a new stake in ADMA Biologics during the first quarter worth about $217,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in ADMA Biologics by 59.6% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 816,590 shares of the biotechnology company’s stock worth $16,201,000 after purchasing an additional 305,064 shares during the period. Cetera Investment Advisers raised its stake in ADMA Biologics by 31.6% during the second quarter. Cetera Investment Advisers now owns 66,495 shares of the biotechnology company’s stock worth $1,211,000 after purchasing an additional 15,984 shares during the period. Finally, Ensign Peak Advisors Inc boosted its holdings in ADMA Biologics by 122.7% in the 2nd quarter. Ensign Peak Advisors Inc now owns 146,012 shares of the biotechnology company’s stock valued at $2,659,000 after purchasing an additional 80,462 shares during the last quarter. 75.68% of the stock is currently owned by hedge funds and other institutional investors.

ADMA Biologics News Roundup

Here are the key news stories impacting ADMA Biologics this week:

• Positive Sentiment: Company issues formal refutation of Culper Research’s allegations, calling the report “unsubstantiated, misleading and inaccurate” and defending ASCENIV’s competitive position and revenue recognition. ADMA refutes short-seller claims
• Positive Sentiment: Market coverage notes a rebound after the company’s rebuttal — headlines and articles report ADMA “gains” as traders react to management’s statements. ADMA gains after refuting claims
• Positive Sentiment: Analysts and media flag market attention including Nasdaq reactions and commentary that the company is actively addressing investor concerns — helpful for short‑term sentiment. Market attention coverage
• Neutral Sentiment: Unusual options activity was reported (large call buying), suggesting speculative positioning that can amplify intraday moves but not fundamental direction. (Options volume reported in market notices.)
• Neutral Sentiment: Context pieces note ADMA is down significantly since its last earnings release, highlighting volatility tied to recent results and expectations — useful for evaluating risk vs. reward. Zacks: stock down since earnings
• Negative Sentiment: Multiple securities‑fraud investigations and investor alerts have been launched by a number of law firms after the short report and the subsequent price decline — this increases legal risk and could pressure the stock. Investor investigations announced
• Negative Sentiment: Short‑seller allegations (including claims of channel stuffing) remain in circulation via reports and investor alerts; third‑party scrutiny prompted steep intraday declines last week and remains a key downside risk. Investor alert on short‑seller report
• Negative Sentiment: Cantor Fitzgerald moved the stock after the short‑report fallout (coverage/ratings action reported), adding analyst pressure on sentiment. Cantor Fitzgerald downgrade

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on the stock. Zacks Research raised shares of ADMA Biologics from a “hold” rating to a “strong-buy” rating in a research note on Monday, March 2nd. Wall Street Zen raised shares of ADMA Biologics from a “hold” rating to a “buy” rating in a report on Saturday, February 28th. Cantor Fitzgerald reiterated a “neutral” rating on shares of ADMA Biologics in a research report on Thursday. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of ADMA Biologics in a research report on Tuesday, December 23rd. Two research analysts have rated the stock with a Strong Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $32.00.

ADMA Biologics Company Profile

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.